AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 12.5 |
Market Cap | 680.68M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -2.46 |
PE Ratio (ttm) | -5.14 |
Forward PE | n/a |
Analyst | Buy |
Ask | 15.25 |
Volume | 497,974 |
Avg. Volume (20D) | 559,993 |
Open | 13.36 |
Previous Close | 13.13 |
Day's Range | 12.41 - 13.41 |
52-Week Range | 11.70 - 34.90 |
Beta | undefined |
About PRTA
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease...
Analyst Forecast
According to 7 analyst ratings, the average rating for PRTA stock is "Buy." The 12-month stock price forecast is $44, which is an increase of 247.83% from the latest price.
Next Earnings Release
Analysts project revenue of $7.53M, reflecting a 2.28K% YoY growth and earnings per share of -1.04, making a -17.46% decrease YoY.